VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XTLB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
XTLBXTL Biopharmaceuticals Ltd.
$2.70$297068
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksXTLBQuarterly Financials

XTL Biopharmaceuticals Ltd. (XTLB) Quarterly Financials

120+ quarters historyFree accessUpdated daily

XTL Biopharmaceuticals Ltd. (XTLB) quarterly income statement — complete revenue, gross profit & net income history

XTLB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q3'21Q2'21Q1'21Q4'20Q3'20Q2'20Q1'20
Sales/Revenue289K162K000000000000000000
Revenue Growth %--------------------
Cost of Goods Sold332K0000000000000000000
COGS % of Revenue114.88%-------------------
Gross Profit-43K162K000000000000000000
Gross Margin %-14.88%100%------------------
Gross Profit Growth %--------------------
Operating Expenses769K926K421K175K200K151K163K251K225K204K202K249K286K442K535K232K257K217K474K257K
OpEx % of Revenue266.09%571.6%------------------
Selling, General & Admin706K756K415K169K194K145K157K238K219K201K187K243K280K424K517K220K245K205K460K254K
SG&A % of Revenue244.29%466.67%------------------
Research & Development32K54K6K6K6K6K6K13K6K3K15K6K6K18K18K12K12K12K14K3K
R&D % of Revenue11.07%33.33%------------------
Other Operating Expenses31K116K000000000000000000
Operating Income-812K-764K-421K-175K-200K-151K-163K-251K-225K-204K-202K-249K-286K-442K-535K-232K-257K-217K-474K-257K
Operating Margin %-280.97%-471.6%------------------
Operating Income Growth %-306%-405.96%-158.28%30.28%11.11%25.98%19.31%-0.8%21.33%53.85%62.24%-7.33%-11.28%-103.69%-12.87%9.73%-5.33%-9.05%-137%-29.15%
EBITDA-762.25K-460K-691K485K-284K-150.75K-162.75K-250.75K-224.75K-203.75K-201.75K-248.75K-285.75K-441.75K-534.75K-231.75K-256.75K0-473.5K0
EBITDA Margin %-263.75%-283.95%------------------
EBITDA Growth %-168.4%-205.14%-324.58%293.42%-26.36%26.01%19.33%-0.8%21.35%53.88%62.27%-7.34%-11.29%--12.94%-----
D&A (Non-Cash Add-back)49.75K304K-270K00250250250250250250250250250250250250217K500257K
EBIT-479K-460K-691K485K-284K-187K-332K-894K-225K-896K-274K515K-286K399K-1.14M-232K-257K-217K-923K-257K
Net Interest Income38K-80K-4K-6K126K-19K-23K-13K27K10K-6K-6K-4K-6K-3K-7K0016K7K
Interest Income2K13K9K10K126K9K9K12K27K10K5K3K005K00025K7K
Interest Expense-36K93K13K16K028K32K25K0011K9K4K6K14K7K009K0
Other Income/Expense427K211K-283K660K-84K-64K-201K-668K-523K-617K-83K755K2.38M-300K-847K518K462K-373K-458K430K
Pretax Income-385K-553K-704K485K-284K-215K-364K-919K-748K-821K-285K506K2.1M-510K-865K286K205K-590K-932K27K
Pretax Margin %-133.22%-341.36%------------------
Income Tax-130K00000000000009K0000-7K
Effective Tax Rate %33.77%0%0%0%0%0%0%0%0%0%0%0%0%0%-1.04%0%0%0%0%-25.93%
Net Income-255K-553K-704K485K-284K-215K-364K-919K-748K-821K-285K506K2.1M-510K-865K286K205K-590K-932K27K
Net Margin %-88.24%-341.36%------------------
Net Income Growth %10.21%-157.21%-93.41%152.77%62.03%73.81%-27.72%-281.62%-135.7%-60.98%67.05%76.92%921.95%13.56%7.19%959.26%118.47%53.06%67.34%-99.3%
Net Income (Continuing)-255K-553K-704K485K-284K-215K-364K-919K-748K-821K-285K506K2.1M-510K-1.15M286K205K-590K-932K173K
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-2.56-6.40-8.325.76-3.20-2.56-4.48-10.88-8.96-9.60-3.205.7623.68-5.76-10.246.40-12.80-7.04-11.520.64
EPS Growth %20%-150%-85.71%152.94%64.29%73.33%-40%-288.89%-137.84%-66.67%68.75%-10%285%18.18%11.11%900%9.09%54.17%67.86%-98.75%
EPS (Basic)-2.56-6.40-8.325.76-3.20-2.56-4.48-10.88-8.96-9.60-3.205.7625.60-6.40-10.246.40-12.80-7.04-11.520.64
Diluted Shares Outstanding110.03K85.15K85.15K85.15K85.14K85.14K85.14K85.14K85.14K85.14K85.14K85.14K90.11K84.04K82.47K82.37K80.34K80.34K80.34K80.34K
Basic Shares Outstanding105.16K85.15K85.15K85.15K85.14K85.14K85.14K85.14K85.14K85.14K85.14K85.14K85.1K82.52K82.47K82.37K80.34K80.34K80.34K80.34K
Dividend Payout Ratio--------------------